Eli Lilly (LLY) Operating Leases (2019)

Eli Lilly (LLY) posted Operating Leases of $608.4 million for Q4 2019, down 0.51% quarter-over-quarter from $611.5 million in Q3 2019.

Eli Lilly (LLY) Operating Leases (2019) Analysis & Trends

Eli Lilly (LLY) has reported Operating Leases for 1 consecutive years, with $608.4 million the latest figure, recorded in Q4 2019.

Operating Leases for Q4 2019 came in at $608.4 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $608.4 million (changed N/A YoY), and the FY2019 annual result was $608.4 million, changed N/A from the prior year.
Operating Leases was $608.4 million for Q4 2019 at Eli Lilly, down from $611.5 million in the prior quarter.
Over five years, Operating Leases peaked at $621.9 million in Q1 2019 and troughed at $503.3 million in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Biogen	30.87 Bn	26.59 Bn	1.82 Bn

Download Data